Monitoring Test Helps Guide Inflammatory Bowel Disease Management
|
By LabMedica International staff writers Posted on 31 Jul 2012 |
|
A new generation test measures drug (infliximab) and drug antibody levels in one sample among inflammatory bowel disease (IBD) patients who use infliximab.
The newly launched test helps physicians to identify potential causes for loss of treatment response and helps to guide patient management decisions.
The new generation test is called Anser IFX and is a product of Prometheus Laboratories Inc., (San Diego, CA, USA). The Anser IFX test was verified with more than 3,000 IBD clinical patient samples. The test uses Prometheus' nonradiolabeled homogeneous mobility-shift assay (HMSA) to measure the antibodies-to-infliximab (ATI) and IFX levels in serum samples.
Approximately 50% of IBD patients using infliximab may eventually experience a loss of treatment response. For some patients, this loss of treatment response may be the result of insufficient infliximab levels. For others, the loss may be due to the development of antibodies to infliximab (ATI). If the loss of treatment response is due to the development of ATI, increasing the infliximab dose–the most common first step for physicians–may be less effective than switching to another treatment agent.
"The need for Prometheus Anser IFX is high, and its availability marks the latest milestone in our continuing commitment to significant advancements in personalized medicine for gastroenterologists, patients, and healthcare providers," said Joseph M. Limber, president and CEO of Prometheus.
Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever, and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. Sometimes the condition is difficult to diagnose, treat, and manage clinically.
Prometheus intends to use this platform for the introduction of additional tests targeted to other biologic agents being used to treat a variety of autoimmune diseases.
Related Links:
Prometheus Laboratories Inc.
 assay.jpg)
The newly launched test helps physicians to identify potential causes for loss of treatment response and helps to guide patient management decisions.
The new generation test is called Anser IFX and is a product of Prometheus Laboratories Inc., (San Diego, CA, USA). The Anser IFX test was verified with more than 3,000 IBD clinical patient samples. The test uses Prometheus' nonradiolabeled homogeneous mobility-shift assay (HMSA) to measure the antibodies-to-infliximab (ATI) and IFX levels in serum samples.
Approximately 50% of IBD patients using infliximab may eventually experience a loss of treatment response. For some patients, this loss of treatment response may be the result of insufficient infliximab levels. For others, the loss may be due to the development of antibodies to infliximab (ATI). If the loss of treatment response is due to the development of ATI, increasing the infliximab dose–the most common first step for physicians–may be less effective than switching to another treatment agent.
"The need for Prometheus Anser IFX is high, and its availability marks the latest milestone in our continuing commitment to significant advancements in personalized medicine for gastroenterologists, patients, and healthcare providers," said Joseph M. Limber, president and CEO of Prometheus.
Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever, and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. Sometimes the condition is difficult to diagnose, treat, and manage clinically.
Prometheus intends to use this platform for the introduction of additional tests targeted to other biologic agents being used to treat a variety of autoimmune diseases.
Related Links:
Prometheus Laboratories Inc.
Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Blood Glucose Test Strip
AutoSense Test
Laboratory Software
ArtelWare
Latest Immunology News
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
- Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
- Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
- Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
- Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
- Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers
- New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read more
Molecular Diagnostics
view channel
Maternal Blood Test Detects Pre-Eclampsia Risk Before Symptoms Develop
Pre-eclampsia remains one of the most dangerous pregnancy complications, yet its cause is difficult to pinpoint because the disorder develops silently and is challenging to study. A major obstacle has... Read more
Blood Test Could Assess Concussion Severity in Teenagers with TBI
Diagnosing and monitoring concussion in adolescents is challenging because symptoms can persist for weeks and vary widely between patients. The need for objective tools is especially urgent for teen girls,... Read more
Simultaneous Analysis of Three Biomarker Tests Detects Elevated Heart Disease Risk Earlier
Accurately identifying individuals at high risk of heart attack remains a major challenge, especially when traditional indicators like cholesterol and blood pressure appear normal. Elevated levels of three... Read more
Hematology
view channel
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreMicrobiology
view channel
15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
Distinguishing minor childhood illnesses from potentially life-threatening infections such as sepsis or meningitis remains a major challenge in emergency care. Traditional tests can take hours, leaving... Read more
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Pathology
view channel
Simple Optical Microscopy Method Reveals Hidden Structures in Remarkable Detail
Understanding how microscopic fibers are organized in human tissues is key to revealing how organs function and how diseases disrupt them. However, these fiber networks have remained difficult to visualize... Read more
Hydrogel-Based Technology Isolates Extracellular Vesicles for Early Disease Diagnosis
Isolating extracellular vesicles (EVs) from biological fluids is essential for early diagnosis, therapeutic development, and precision medicine. However, traditional EV-isolation methods rely on ultra... Read more
Technology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read more
Industry
view channel
Roche and Freenome Collaborate to Develop Cancer Screening Tests
Roche (Basel, Switzerland) and Freenome (Brisbane, CA, USA have entered into a strategic collaboration to commercialize Freenome's cancer screening technology in international markets.... Read more
